ScreenerHero

INVA Innoviva, Inc.

NAS · US · Healthcare · Biotechnology · inva.com
20.87USD-0.90%Mkt Cap: 1.51B $P/E: 4.88

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
JAZZ
Jazz Pharmaceuticals plc
$14.44BUSDP/E 15.2
SMMT
Summit Therapeutics Inc.
$13.70BUSD

Key Statistics

Company
Market Cap1.51B USD
Enterprise Value1.26B USD
Revenue (TTM)440.00M USD
Gross Profit333.94M USD
Net Income (TTM)271.17M USD
Revenue/Share6.04 USD
Last Price20.87 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees159
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)4.88
P/E (Forward)9.43
PEG3.09
EV/EBITDA6.43
EV/Revenue2.86
P/S3.42
P/B1.23
EPS (TTM)4.31
EPS (Forward)2.21
52W Range
16.5250% of range25.15
52W High25.15 USD
52W Low16.52 USD
Profitability
Gross Margin81.19%
Oper. Margin43.28%
EBITDA Margin44.41%
Profit Margin65.92%
ROE23.12%
ROA16.58%
Growth
Revenue Growth19.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF196.93M USD
CapEx (TTM)10.50M USD
FCF Margin25.08%
FCF Yield7.32%
Net Debt-247.82M USD
Net Debt/EBITDA-1.27
Balance Sheet
Debt/Equity0.23
Current Ratio16.01
Quick Ratio14.65
Book Value/Sh16.98 USD
Cash/Share8.02 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateSep 8, 2015
Pay DateSep 30, 2015
Splits
Last Split1241:1000
Split DateJun 3, 2014
Analyst Consensus
Rating1.8 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)35.00 USD
Upside (mean)+67.7%
Target Range18.00 USD – 46.00 USD
18.00+67.7% to mean46.00
# Analysts5
Ownership
Shares Out.72.25M
Float67.65M
Insiders1.01%
Institutions108.77%
Short Interest
Short Ratio10.5d
Short % Float13.43%
Short % Out.9.89%
Shares Short7.14M
Short (prev mo.)6.86M
Technical
SMA 5020.98 (-0.5%)
SMA 20021.77 (-4.1%)
Beta0.38
S&P 52W Chg16.45%
Avg Vol (30d)821.40K
Avg Vol (10d)1.19M
Technical Indicators
RSI (14)48.8
MACD-0.0776
MACD Signal-0.0967
MACD Hist.+0.0190
BB Upper21.43 USD
BB Middle20.87 USD
BB Lower20.31 USD
BB Width5.37%
ATR (14)0.4629 USD
Vol Ratio (20d)0.60x